By admin 
When the announcement arrived on Wednesday that the Department of Defense (DOD) would initiate a mandatory testosterone screening program for all service members, the news sent shockwaves through both the military establishment and the medical community. For those who have dedicated their careers to the study of men’s health and the intricacies of population-level screening, the proposal raises a litany of urgent questions. While the initiative is ostensibly aimed at optimizing the physical readiness and hormonal health of the American fighting force, the widespread rollout of such a program may precipitate a series of surprising and unintended consequences. These risks must be meticulously weighed against the perceived benefits if the ultimate goal is the long-term health and operational efficacy of U.S. service members.
As a practicing urologist and health outcomes researcher, I have occupied a front-row seat to the burgeoning cultural and medical fascination with testosterone supplementation. Over the last decade, interest in "T-therapy" has transitioned from a niche medical treatment for specific endocrine disorders to a mainstream wellness phenomenon. My research has specifically delved into the implementation of various screening tests within the military population, and the data suggests that any large-scale medical intervention carries hidden complexities. The DOD’s decision to mandate testosterone testing is not merely a policy shift; it is an unprecedented medical experiment on a captive population, and the downstream effects could be as thorny as they are permanent.
To understand the stakes, one must first understand the biology. Testosterone is far more than a "male" hormone associated with strength and aggression; it is a vital chemical messenger produced through a highly calibrated feedback loop known as the hypothalamic-pituitary-gonadal (HPG) axis. This system involves a complex dialogue between the brain and the testes, beginning in utero to develop male reproductive organs and peaking during puberty to drive the physical transformations of manhood. Beyond its role in sexual development, testosterone influences bone density, fat distribution, red blood cell production, and mood. However, because it is part of a delicate equilibrium, external interference with this system can lead to systemic disruptions.
In the clinical world, the management of testosterone as men age is a subject of intense debate. It is a biological fact that testosterone levels gradually decline as men get older, a process sometimes colloquially referred to as "andropause." Many symptoms of natural aging—increased body fat, decreased bone mineral density (osteoporosis), and a waning libido—overlap with the clinical symptoms of hypogonadism. Furthermore, the HPG axis is sensitive to external factors. Obesity, sedentary lifestyles, chronic stress, and poor diet can all suppress natural testosterone production. This creates a diagnostic challenge: is a service member’s low testosterone a primary medical deficiency, or is it a secondary symptom of lifestyle factors, sleep deprivation, or the extreme physical toll of military service?
The backdrop of this DOD mandate is a global market for testosterone therapy that has experienced an astronomical expansion. In the late 1980s, global sales of testosterone products totaled a mere $18 million annually. By 2025, that figure is projected to reach nearly $2 billion. This growth has not been driven solely by clinical necessity but by an aggressive ecosystem of direct-to-consumer marketing, "men’s health" lifestyle brands, and online influencers who frame testosterone as a panacea for everything from brain fog to career dissatisfaction. In my practice, I have seen the fallout of this "wellness" surge. Patients frequently arrive having obtained hormones through loosely regulated online platforms, sometimes presenting with testosterone levels five to ten times higher than the physiological norm—levels that are not only unnecessary but potentially dangerous.
There is no denying that for men with legitimate clinical deficiencies, testosterone replacement therapy (TRT) can be transformative. It can increase lean muscle mass, improve bone density, and enhance libido. In the context of the military, where physical "lethality" is a core metric, these benefits are clearly attractive to leadership. However, the medical community remains divided on the long-term safety profile of widespread supplementation, particularly in men who do not meet the strict criteria for classic hypogonadism.
Historical data provides a cautionary tale. In 2010, the Testosterone in Older Men with Mobility Limitations (TOM) study was abruptly halted by safety monitors. The trial found that men receiving testosterone had a significantly higher incidence of major adverse cardiac events, including heart attacks and strokes, compared to the placebo group. While more recent data, such as the 2023 TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), offered some reassurance by showing no statistically significant increase in major cardiac events, it was not a clean bill of health. The TRAVERSE study instead highlighted a "higher incidence" of other serious complications, including acute kidney injury, atrial fibrillation, and pulmonary embolism.
My own research team has spent years analyzing the health outcomes of military service members specifically. Utilizing data from the military’s health insurance system, TRICARE, we investigated the side effects of testosterone supplementation among beneficiaries. Our findings, supported by the DOD, revealed a complicated picture. Military members using testosterone supplements showed higher rates of kidney stones and obstructive sleep apnea. Interestingly, while one of our studies indicated an improvement in certain cardiovascular outcomes, the trade-offs—particularly the increased risk of respiratory issues during sleep—are significant for active-duty personnel who are often required to operate in high-stress, low-oxygen, or austere environments.
Perhaps the most critical concern for the active-duty population involves reproductive health. Defense Secretary Pete Hegseth noted that the screening program would target service members ages 30 and older—a demographic that is often in its peak years for starting or expanding families. It is a well-documented medical reality that exogenous testosterone (testosterone taken from outside the body) acts as a form of male contraception. It signals the brain to stop producing the hormones that stimulate the testes, which in turn leads to a reduction in testicle size and a plummeting sperm count. Both the American Urological Association and the Endocrine Society explicitly caution against the use of testosterone in men who desire future fertility. If thousands of service members are funneled into supplementation programs without rigorous counseling on this side effect, the DOD could inadvertently preside over a fertility crisis within the ranks.
Furthermore, the logistics of accurate testing present a significant hurdle. Testosterone levels are diurnal, meaning they fluctuate throughout the day, typically peaking in the early morning. A single "low" reading in the afternoon or after a night of poor sleep (a common occurrence for soldiers) is not a diagnosis. To confirm hypogonadism, clinical guidelines require at least two separate early-morning tests, alongside the measurement of other markers such as Luteinizing Hormone (LH) and sex hormone-binding globulin (SHBG). Without these rigorous protocols, the military risks a high rate of false positives, leading to unnecessary and lifelong medicalization.
The current Endocrine Society guidelines are clear: they recommend against routine population-level screening of asymptomatic men for hypogonadism. They also advise against routine supplementation for younger men with low levels unless a specific underlying disease is identified. The DOD’s directive stands in direct opposition to these established medical standards. By mandating screening, the military is effectively searching for a "problem" that the world’s leading endocrine experts suggest should only be addressed when a patient proactively seeks care for specific symptoms.
Secretary Hegseth has stated that the decision to supplement will remain with the individual service member. However, the power dynamic of the military cannot be ignored. When a superior officer or a government mandate labels a soldier’s hormone levels as "deficient," the pressure to "fix" that deficiency to remain competitive for promotion or deployment is immense. To mitigate this, the DOD must ensure that every service member receives individualized counseling that covers the full spectrum of risks—from the potential for blood clots and kidney issues to the loss of fertility.
Implementing a personalized monitoring system at the scale of the entire Department of Defense will be a logistical Herculean task. Each member on therapy will require regular blood work to monitor red blood cell counts (to prevent polycythemia, a thickening of the blood) and prostate-specific antigen (PSA) levels. This is not a "fire and forget" medical intervention; it is a lifelong commitment to monitoring.
Ultimately, the decision to roll out widespread testosterone testing represents a novel experiment with no precedent in modern medicine. While the drive to ensure a healthy and capable force is commendable, the path forward must be paved with scientific rigor rather than cultural trends. For the long-term wellness of those who serve, it is vital that this program is governed by clinical evidence and a deep respect for the complexity of human physiology. Without careful oversight, the quest for a more "potent" military may result in a generation of veterans facing chronic health challenges that were entirely preventable.
